Home > Back to Publisher > Report Information

Analysis of Oncology Deals: Trends in Deal Structures and Valuations

PharmaVentures Ltd.
December 1, 2009
SKU: PHV2514699

Abstract Table of Contents Related Reports

Analysis of Oncology Deals: Trends in Deal Structures and Valuations

This must-have new report contains key oncology market data, essential in answering the following questions:

Who are the top players operating within oncology and who are the smaller companies to watch out for and partner with?
What is the impact of the credit crunch in oncology deal making and are the emerging markets having any significant effect on this therapy area?
Which technologies are driving the deals and why are they attractive?

It contains:

An analysis of deal making trends and valuations by deal type, by stage of development and by territory, to provide pointers to what is likely to happen in oncology
An analysis of royalty rates in oncology
A comprehensive reference section with case studies of handpicked deals with analysis of SEC contracts
Deal making activity of the top companies in oncology

Who should read this report?

Corporate strategists and all senior managers
Business development and deal makers
Marketing and competitive intelligence executives
Senior managers in R&D and technology transfer
Analysts, consultants, venture capitalists and those within the finance sector serving the pharma and biotech industry

1 Introduction to oncology: 1.1 Cancer; 1.2 Incidence and mortality; 1.3 Disease impact and economic burden; 1.4 Market size; 1.5 Market trends; 1.6 Current therapies; 1.8 Key players
2 Overall trends in oncology deals: 2.1 Comparison with other therapy areas; 2.2 Total number of oncology deals; 2.3 Total value of oncology deals
3 Analysis of oncology deals by deal type: 3.1 Types of oncology deals; 3.2 Year on year analysis by deal type; 3.3 Deal type by value
4 Oncology deals by stage of development: 4.1 Number of oncology deals by stage of development; 4.2 Type of deal by stage of development; 4.3 Year on year analysis of oncology deals by stage of development; 4.4 Value of oncology deals by stage of development; 4.5 Case studies
5 Oncology deals by territory: 5.1 Analysis of oncology deals by territory; 5.2 Year on year analysis of oncology deals by territory
6 Oncology deals by product type: 6.1 Oncology deals by product type (August 2008 to July 2009); 6.2 Diagnostics; 6.3 Vaccines; 6.4 Oncology deals by product type (August 2008 to July 2009)
7 Analysis of royalties in oncology deals: 7.1 Overview; 7.2 Case studies; 7.3 Conclusions
8 Key players in oncology deal making: 8.1 Analysis of the top ten dealmakers - companies
9 Conclusions
10 Appendix 1: Deal type by value
11 Appendix 2
Case studies: High value deals by stage of development: 11.1 Pre-clinical; 11.2 Phase I; 11.3 Phase II; 11.4 Phase III; 11.5 Launched
12 Appendix 3: Reference to Deals in the Report
Tables: 1 Top oncology brands 2007; 2 Top 5 oncology drugs 2014; 3 All compounds in development for oncology indications (September 2009); 4 Compounds in development for oncology (excluding those in later stage development in other therapy areas) (September 2009); 5 Key players in oncology based on sales value, 2008; 6 Selected acquisition deals 2008/9; 7 Deal type by value (1997 to July 2009); 8 Deals by type and stage of development (1997 to July 2009); 9 Year on year analysis of deals by territory (1997 to July 2009); 10 Selected antibody based deals 2008; 11 Royalty rate percentages by development stage in oncology deals (1997 to July 2009); 12 Top twenty oncology dealmakers (1997 to July 2009); 13 Top twenty oncology dealmakers (2000 to July 2009); 14 Top seventeen deal making companies (2005 to July 2009); 15 Top three public institutes (2005 to July 2009); 16 Comparison of the ranking of the top oncology companies
Figures: 1 Deal intensity by therapeutic area (1997 to July 2009); 2 Total oncology deals by year (1997 to July 2009); 3 Total oncology deal values (1997 to July 2009); 4 Deal numbers and deal values excluding M&A (1997 to July 2009); 5 Total deals by type (1997 to July 2009); 6 Further breakdown of Collaborative/Licensing deal types (1997 to July 2009); 7 Year on year analysis of deal types showing total deal numbers per year (1997 to July 2009); 8 Year on year analysis of deal types showing individual deal type trends year on year (1997 to July 2009); 9 Year on year analysis of Collaborative/Licensing deal types (1997 to July 2009); 10 Value of deals by type - lower to upper quartiles (1997 to July 2009); 11 Number of deals by stage of development (1997 to July 2009); 12 Deals by type and stage of development (1997 to July 2009); 13 Year on year analysis of deals by stage of development (1997 to July 2009); 14 Average value of deals by stage of development (1997 to July 2009); 15 Number of deals by territory (1997 to July 2009); 16 Year on year analysis of deals by territory (1997 to July 2009); 17 Oncology deals by product type (1997 to July 2009); 18 Disclosed royalty rates for selected oncology deals (1997 to July 2009); 19 Collaborative/Licensing deal values by frequency and range (1997 to July 2009); 20 Marketing deal values by frequency and range (1997 to July 2009); 21 Technology Access deal values by frequency and range (1997 to July 2009); 22 Finance deal values by frequency and range (1997 to July 2009); 23 Manufacture deal values by frequencyand range (1997 to July2009)

Analysis of Oncology Deals: Trends in Deal Structures and Valuations

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service